Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20 percent in adults with overweight or obesity and established cardiovascular disease who don’t have diabetes. A. Michael Lincoff, MD, SELECT’s lead author and vice chair for research in Cleveland Clinic’s Department of Cardiovascular Medicine, provides an overview of the SELECT trial and findings.